Pharmaceutical

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions

The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.

Jan 19, 2024 - 18:00
Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions
The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.
Read the original article

Tags:

Previous Article

argenx’s VYVDURA gains approval in Japan for gMG treatment

Next Article

Davos: AI Governance Alliance calls for stronger global collaboration

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Generate Biomedicines partners with MD Anderson to develop cancer therapies

Generate Biomedicines partners with MD Anderson to deve...

Apr 28, 2023

Sun Pharma and Philogen sign licence agreement for anti-cancer therapy

Sun Pharma and Philogen sign licence agreement for anti...

May 30, 2023

STAT+: Senate committee plans Nov. 8 vote on wide-ranging health care package

STAT+: Senate committee plans Nov. 8 vote on wide-rangi...

Oct 30, 2023